I dont think it has anything to do with the trials. It has to do with them announcing they would be looking for partnerships to share this testing method with. Actually, this seems like it is good news. Yes, they would have to share the revenue they make of it, but it also means they probably won't be any dilution to shareholders. May be a nice candidate for a buyout. This testing method looks like it's going to be a winner. Probably will see a spike up tomorrow. Im going to try to grab some shares cheap in The am.
News 
Market Data 
Discover 
AI
